<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - GOLIMUMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>GOLIMUMAB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of severe ulcerative colitis in patients whose condition has not responded adequately to conventional therapy, or who are intolerant of it</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 80 kg)</strong><br/>
                Initially 200 mg, then 100 mg after 2 weeks; maintenance 50 mg every 4 weeks, review treatment if no response after 4 doses.</li>
              <li class="dose adult"><strong>For adults (body-weight 80 kg and above)</strong><br/>
                Initially 200 mg, then 100 mg after 2 weeks; maintenance 100 mg every 4 weeks, review treatment if no response after 4 doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of moderate to severe active rheumatoid arthritis (in combination with methotrexate) when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate</span>,
                <span class="indication">Treatment of severe, active, and progressive rheumatoid arthritis (in combination with methotrexate) in patients not previously treated with methotrexate</span>,
                <span class="indication">Treatment of active and progressive psoriatic arthritis as monotherapy or in combination with methotrexate when response to DMARD therapy has been inadequate</span>,
                <span class="indication">Treatment of severe active ankylosing spondylitis when there is inadequate reponse to conventional treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 100 kg)</strong><br/>
                50 mg once a month, on the same date each month, review treatment if no response after 3&#8211;4 doses.</li>
              <li class="dose adult"><strong>For adults (body-weight 100 kg and above)</strong><br/>
                Initially 50 mg every 1 month for 3&#8211;4 doses, on the same date each month, dose may be increased if inadequate response, increased to 100 mg once a month, review treatment if inadequate response to this higher dose after 3&#8211;4 doses.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if essential.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises caution&#8212;no information available.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Moderate or severe heart failure</li>
            <li>severe active infection</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Asthenia, dizziness, dyspepsia, hypertension,
              </p>
              <p>
                <strong>uncommon:</strong> Alopecia, arrhythmia, bone fractures, bronchospasm, cholelithiasis, colitis, constipation, demyelinating disorders, dermatitis, eye irritation, flushing, gastritis, gastro-oesophageal reflux disease, heart failure, hepatic disorders, hyperglycaemia, hyperlipidaemia, insomnia, interstitial lung disease, ischaemic coronary artery disorders, lymphoma, malignancy, melanoma, menstrual disorders, new onset or worsening psoriasis, paraesthesia, Raynaud&#8217;s syndrome, stomatitis, taste disturbance, thrombosis, thyroid disorders, visual disturbance,
              </p>
              <p>
                <strong>rare:</strong> Impaired wound healing,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal pain, anaemia, antibody formation, aplastic anaemia, blood disorders, depression, fever, headache, hypersensitivity reactions, injection-site reactions, leucopenia, lupus erythematosus-like syndrome, nausea, pancytopenia, pruritus, thrombocytopenia, worsening heart failure,
              </p>
        
        
            <section class="advice">
              <p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>For doses requiring multiple injections, each injection should be administered at a different site.</p>
            </section>
            <section class="directionsForAdministration">
                <h3>Missed dose</h3>
              <p>If dose administered more than 2 weeks late, subsequent doses should be administered on the new monthly due date.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Tuberculosis</h3>
              <p>All patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Blood disorders</h3>
              <p>Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.</p>
            </section>
            <section class="patientResources">
              <p>An alert card should be provided.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA220</h3>
              <p outputclass="title">Golimumab for the treatment of psoriatic arthritis (April 2011)</p> <p>Golimumab is an option for the treatment of active and progressive psoriatic arthritis in adults only if:</p> <ul> <li>golimumab is used as described in the NICE guidance (August 2010) for other tumour necrosis factor (TNF) inhibitors, <i>and</i> </li> <li>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA220">www.nice.org.uk/TA220</xref>
                <a href="http://www.nice.org.uk/TA220" target="_blank">www.nice.org.uk/TA220</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA225</h3>
              <p outputclass="title">Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs (June 2011)</p> <p>Golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) only, including methotrexate, if:</p> <ul> <li>golimumab is used as described in the NICE guidance (October 2007) for other tumour necrosis factor (TNF) inhibitors, <i>and</i> </li> <li>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.</li> </ul> <p>Alternatively, golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in adults who have had an inadequate response to DMARDs including a TNF inhibitor, if:</p> <ul> <li>golimumab is used as described in the NICE guidance (August 2010) for other TNF inhibitors, <i>and</i> </li> <li> the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA225">www.nice.org.uk/TA225</xref>
                <a href="http://www.nice.org.uk/TA225" target="_blank">www.nice.org.uk/TA225</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA233</h3>
              <p outputclass="title">Golimumab for the treatment of ankylosing spondylitis (August 2011)</p> <p>Golimumab is an option for the treatment of severe, active ankylosing spondylitis in adults only if:</p> <ul> <li>Golimumab is used as described in the NICE guidance (May 2008) for adalimumab and etanercept, <i>and</i> </li> <li>the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.</li> </ul> <p>Patients who are already receiving golimumab for the treatment of severe, active ankylosing spondylitis who do not fulfil the criteria for treatment with adalimumab and etanercept, described in the NICE guidance (May 2008), can continue treatment until they and their specialist consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA233">www.nice.org.uk/TA233</xref>
                <a href="http://www.nice.org.uk/TA233" target="_blank">www.nice.org.uk/TA233</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA329</h3>
              <p outputclass="title">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)</p> <p>Golimumab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.</p> <p>Golimumab is recommended only if the manufacturer provides the 100&#8239;mg dose of golimumab at the same cost as the 50&#8239;mg dose, as agreed in the patient access scheme.</p> <p>The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.</p> <p>Golimumab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.</p><xref format="html" href="http://www.nice.org.uk/TA329">www.nice.org.uk/TA329</xref>
                <a href="http://www.nice.org.uk/TA329" target="_blank">www.nice.org.uk/TA329</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active infection (do not initiate until active infections are controlled; discontinue if new serious infection develops until infection controlled)
          </li>
          <li>
            demyelinating disorders (risk of exacerbation)
          </li>
          <li>
            hepatitis B virus&#8212;monitor for active infection
          </li>
          <li>
            history or development of malignancy
          </li>
          <li>
            mild heart failure (discontinue if symptoms develop or worsen)
          </li>
          <li>
            predisposition to infection
          </li>
          <li>
            risk factors for dysplasia or carcinoma of the colon&#8212;screen for dysplasia regularly
          </li>
        </ul>
        <ul>
          <li>
            <p>Active tuberculosis should be treated with standard treatment for at least 2 months before starting golimumab. Patients who have previously received adequate treatment for tuberculosis can start golimumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting golimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with golimumab. Patients who have tested negative for latent tuberculosis, and those who are receiving or who have completed treatment for latent tuberculosis, should be monitored closely for symptoms of active infection.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer advises adequate contraception during treatment and for at least 6 months after last dose.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for infection before, during, and for 5 months after treatment.</p>
            </section>
      </section>






      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
                <h3>Tuberculosis</h3>
              <p>Patients should be evaluated for tuberculosis before treatment.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of GOLIMUMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77465"><a href="../medicinalForm/PHP77465.html" data-target="#PHP77465" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
